US OptionsDetailed Quotes
LLY241206C660000
- 139.74
- 0.000.00%
15min DelayClose Dec 3 16:00 ET
0.00High0.00Low
139.74Open139.74Pre Close0 Volume3 Open Interest660.00Strike Price0.00Turnover0.00%IV-1.67%PremiumDec 6, 2024Expiry Date153.33Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.82Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Eli Lilly and Co Stock Discussion
Sign in to post a comment
Columns US Morning News Call | Futures Climb on Positive Earnings, Focus Shifts to Upcoming Speech by Powell
$S&P Global (SPGI.US)$ $Nasdaq (NDAQ.US)$ $Dow Inc (DOW.US)$ $iShares 20+ Year Treasury Bond ETF (TLT.US)$ $Direxion Daily Semiconductor Bull 3x Shares ETF (SOXL.US)$ $Tesla (TSLA.US)$ $Microsoft (MSFT.US)$ $United States Steel (X.US)$ $NVIDIA (NVDA.US)$ $U.S. 10-Year Treasury Notes Yield (US10Y.BD)$ $Marvell Technology (MRVL.US)$ $Salesforce (CRM.US)$ $Eli Lilly and Co (LLY.US)$
Expand 7
1
$Eli Lilly and Co (LLY.US)$ why tf did it go back down as soon as it went up?!
1
1
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
🚒🧯🚒🧯🚒🧯🚒🔥🔥🔥🔥🔥🔥🔥🚨🚨🚨🚨🚨
Don’t Miss The Wave 🌊 🏄♂️
STOCKS WITH AMAZING ROI %
$Vistra Energy (VST.US)$ is overlooked but outperformed most stocks in 2024
$NVIDIA (NVDA.US)$ as well as
SEZL DAVE LBPH ROOT SMR APP SUMMIT LUNR MSTR
.
Historic 2 Weeks Nov 25-29 December 2-7
• TOP TIER
BTC to $100K *
ETH to $4,000 *
NOW to $1041
LLY to $788.19
BRK.B to $483 *
MSFT to $423
PANW to $384.37
CRWD to $347.59
TSLA to $333 *
APP to $328.5...
Don’t Miss The Wave 🌊 🏄♂️
STOCKS WITH AMAZING ROI %
$Vistra Energy (VST.US)$ is overlooked but outperformed most stocks in 2024
$NVIDIA (NVDA.US)$ as well as
SEZL DAVE LBPH ROOT SMR APP SUMMIT LUNR MSTR
.
Historic 2 Weeks Nov 25-29 December 2-7
• TOP TIER
BTC to $100K *
ETH to $4,000 *
NOW to $1041
LLY to $788.19
BRK.B to $483 *
MSFT to $423
PANW to $384.37
CRWD to $347.59
TSLA to $333 *
APP to $328.5...
+55
78
19
5
well said Bro 
Today, $Amgen (AMGN.US)$ announced the P2 trial results for MariTide, which only include the safety profile for the 420 mg dose escalation cohorts (cherry-picking at it's finest again).
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
+1
3
$Eli Lilly and Co (LLY.US)$ Bio season gonna kick off early
1
No comment yet
upton :